Moderna has secured FDA approval for its messenger RNA-based influenza vaccine, marking a significant milestone in the evolution of seasonal flu shot technology.
The approval, announced late Wednesday, covers adults aged 50 and older, opening up a substantial segment of the population to the new vaccine option.
Known throughout its development by the code name mRNA-1010, the vaccine will reach the market under the brand name mFLUSIVA ahead of the upcoming respiratory virus season.
The shot joins a growing Moderna respiratory products lineup that already includes mRNA vaccines targeting Covid-19 and respiratory syncytial virus, known as RSV.
Moderna’s mRNA platform offers a key technological advantage over traditional flu vaccines, enabling faster adjustments in response to viral mutations as strains evolve.
Traditional flu vaccines have historically been manufactured from egg or cell culture, a process that takes months from start to finish before doses can reach patients.
Because of that lengthy production timeline, decisions on which strains to target each season must be made well in advance, leaving limited room to respond to late-breaking mutations.
That vulnerability played out last flu season, when the available vaccines turned out to be mismatched to the strain that ultimately became dominant across the population.
The vaccines still offered some protection, but that protection was meaningfully diminished because of the mismatch between the targeted and circulating strains.
Moderna’s mRNA technology could reduce that risk in future seasons by allowing faster reformulation if surveillance data shows that dominant strains are shifting unexpectedly.
The company confirmed it will make mFLUSIVA available for the upcoming respiratory virus season, though the timing of broader rollout will depend in part on further regulatory and public health guidance.
CDC input on vaccine recommendations for the season remains uncertain, a factor that could influence how widely the shot is adopted by healthcare providers and payers.
Moderna has positioned its mRNA platform as a pipeline capable of addressing multiple respiratory threats under a single unified technology architecture heading into 2026 and beyond.